Biodexa Pharmaceuticals PLC 6-K Filing

FAQ

Key Financial Figures

• $3 — ed offering price for each ADS Unit was $3.28, and the combined offering price for
• $3.2799 — ring price for each Pre-Funded Unit was $3.2799. The Pre-Funded Warrants will have an e
• $0.0001 — Warrants will have an exercise price of $0.0001 per ADS, will be immediately exercisabl
• $3.28 — Warrants will have an exercise price of $3.28 per ADS, will be immediately exercisabl
• $8.75 million — rrants, is expected to be approximately $8.75 million. The Company intends to use the net pro
• $100,000 — counsel for the placement agent, up to $100,000, and will pay the Placement Agent a fee
• $20,460 — ADSs for an aggregate purchase price of $20,460 (the “ Nominal Value Amount &rdqu

Filing Documents

• y12172516k.htm (6-K) — 32KB
• ex4_1.htm (EX-4.1) — 102KB
• ex4_2.htm (EX-4.2) — 95KB
• ex4_3.htm (EX-4.3) — 104KB
• ex10_1.htm (EX-10.1) — 215KB
• ex10_2.htm (EX-10.2) — 107KB
• ex99_1.htm (EX-99.1) — 14KB
• 0001214659-25-018196.txt ( ) — 670KB

Forward-Looking Statements

Forward-Looking Statements This Report on Form 6-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the anticipated closing of the Offerings and the amount of proceeds expected from the Offerings. The risks and uncertainties involved include the Company’s ability to satisfy certain conditions to closing on a timely basis or at all, market conditions, and other risks detailed from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this report on Form 6-K. The Company does not intend to revise or update any forward-looking statement in this report on Form 6-K as a result of new information, future events or otherwise, except as required by law. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of December 2025, and incorporated by reference herein, is: Exhibit No. Description 4.1 Form of Series L Warrant. 4.2 Form of Pre-Funded Warrant. 4.3 Form of Placement Agent Warrant. 10.1 Form of Securities Purchase Agreement, dated as of December 17, 2025, by and between Biodexa Pharmaceuticals PLC and the investors identified on the signature pages thereto.* 10.2 Placement Agency Agreement, dated as of December 17, 2025, by and between Biodexa Pharmaceuticals PLC and the Maxim Group LLC. 99.1 Press release dated December 18, 2025. * Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereun

View Full Filing

View this 6-K filing on SEC EDGAR